IRTC
Company Description
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 747.14M | 591.84M | 492.68M | 410.92M | 322.82M | 265.17M | 214.55M | 147.28M | 99.13M | 64.07M | 36.14M | 21.75M |
| Net Income | (44.55M) | (113.29M) | (123.41M) | (116.16M) | (101.36M) | (43.83M) | (54.57M) | (50.38M) | (29.74M) | (20.90M) | (22.80M) | (15.83M) |
| EPS | -1.39 | -3.63 | -4.04 | -3.88 | -3.46 | -1.58 | -2.16 | -2.02 | -1.30 | -3.95 | -1.54 | -1.07 |
| Free Cash Flow | 34.52M | (30.55M) | (90.53M) | (52.84M) | (65.82M) | (27.31M) | (42.32M) | (34.25M) | (18.47M) | (19.41M) | N/A | N/A |
| FCF / Share | 1.08 | -0.98 | -2.97 | -1.77 | -2.24 | -0.98 | -1.67 | -1.43 | -0.82 | -3.67 | N/A | N/A |
| Operating CF | 80.86M | 3.39M | (50.10M) | (23.01M) | (37.75M) | (13.76M) | (21.86M) | (29.07M) | (14.91M) | (16.65M) | N/A | N/A |
| Total Assets | 1.02B | 931.45M | 433.14M | 448.22M | 462.97M | 511.74M | 306.21M | 119.71M | 133.12M | 138.16M | N/A | N/A |
| Total Debt | 731.18M | 736.91M | 129.82M | 131.04M | 117.71M | 122.47M | 128.59M | 34.90M | 33.98M | 32.23M | N/A | N/A |
| Cash & Equiv | 236.01M | 419.60M | 36.17M | 78.83M | 127.56M | 88.63M | 20.46M | 20.02M | 8.67M | 51.64M | N/A | N/A |
| Book Value | 152.75M | 90.91M | 210.10M | 239.81M | 279.51M | 341.61M | 135.41M | 54.42M | 79.55M | 92.56M | N/A | N/A |
| Return on Equity | -0.29 | -1.25 | -0.59 | -0.48 | -0.36 | -0.13 | -0.40 | -0.93 | -0.37 | -0.23 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 199.39M | 208.89M | 192.88M | 186.69M | 158.68M | 164.32M | 147.54M | 148.05M | 131.93M | 132.51M | 124.60M | 124.13M |
| Net Income | (13.93M) | 5.58M | (5.21M) | (14.22M) | (30.70M) | (1.33M) | (46.18M) | (20.11M) | (45.67M) | (38.70M) | (27.12M) | (18.48M) |
| EPS | -0.43 | 0.17 | -0.16 | -0.44 | -0.97 | -0.04 | -1.48 | -0.65 | -1.47 | -1.26 | -0.89 | -0.61 |
| Free Cash Flow | (33.08M) | 14.49M | 20.05M | 17.29M | (17.31M) | 12.39M | 15.51M | 3.35M | (61.80M) | (29.49M) | (7.89M) | (13.97M) |
| FCF / Share | -1.02 | 0.45 | 0.62 | 0.54 | -0.55 | 0.40 | 0.50 | 0.11 | -1.99 | -0.96 | -0.26 | -0.46 |
| Operating CF | (26.17M) | 26.21M | 34.88M | 27.66M | (7.89M) | 19.23M | 24.35M | 11.84M | (52.03M) | (15.97M) | 1.20M | (4.57M) |
| Total Assets | 1.01B | 1.02B | 995.21M | 964.03M | 926.10M | 931.45M | 909.69M | 919.18M | 909.75M | 433.14M | 439.77M | 429.49M |
| Total Debt | 729.29M | 731.18M | 733.01M | 734.74M | 735.50M | 736.91M | 735.36M | 736.54M | 737.00M | 129.82M | 131.74M | 129.28M |
| Cash & Equiv | 240.15M | 236.01M | 255.60M | 309.11M | 375.28M | 419.60M | 519.53M | 550.55M | 520.42M | 36.17M | 47.48M | 61.58M |
| Book Value | 161.21M | 152.75M | 121.89M | 103.66M | 86.67M | 90.91M | 71.77M | 99.19M | 90.29M | 210.10M | 219.79M | 223.88M |
| Return on Equity | -0.09 | 0.04 | -0.04 | -0.14 | -0.35 | -0.01 | -0.64 | -0.20 | -0.51 | -0.18 | -0.12 | -0.08 |